Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>Products>This Product
  Products


Rapid Biologics Development to Maximize your Speed to Clinic

Product Image
Product Description

Whether you are using a Catalent GPEx® technology-based cell line or a client-derived cell line, we can design a process for your project that can be easily transferred to our production plant. All operations from cell line development through production of preclinical and/or clinical (Phase I/II) API can be performed in a single facility with a dedicated project manager – thus ensuring better continuity and reliability. Backed by experts in the fields of molecular biology, cell line development, process development, biopharmaceutical manufacturing, and quality systems, we are able to streamline processes, and enhance performance, and speed through to clinical production.

Catalent Services

• Generation of master and working cell banks
• Cell line stability studies
• Upstream process development in shake flask and bioreactor systems (2L - 10L)
• Downstream process development at the milligram to 100s gram scale
• Scale down and non-cGMP production (up to 100L) in disposable and stainless bioreactors
• cGMP manufacturing of Phase I / Phase II material in product-dedicated suites using stirred tank bioreactors at the 200L scale

Product Rapid Biologics Development to Maximize your Speed to Clinic
Company Catalent Pharma Solutions
Price Request a quote
More Information View company product page
Catalog Number Unspecified
Quantity Unspecified
Company Logo

Catalent Pharma Solutions
Sedge Close, Headway, Great Oakley Corby, Northamptonshire NN18 8HS, England

Tel: 44 (0) 1536 461146
Fax: 44 (0) 1536 461011
Email: info@catalent.com



Scientific News
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
First Made-in-Singapore Cancer Drug Enters Clinical Testing
The drug prevents cancer progression and paves the way for new advancements in cancer therapeutics.
Scroll Up
Scroll Down

SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!